Cardiff Oncology, Inc. 8K

Cardiff Oncology reported Q2 2026 results, advanced its onvansertib program toward a Phase 3 trial in RAS-mutated mCRC, disclosed litigation over its key license, and completed a $10 million registered direct offering to extend its cash runway.

On August 11, 2026, Cardiff Oncology, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a business update, highlighting positive Phase 2 CRDF-004 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer presented at ASCO, alignment with the FDA on key design elements for a planned registrational Phase 3 trial expected to initiate in Q1 2027 subject to additional financing, new preclinical data supporting combination use with antibody-drug conjugates, an ongoing licensing dispute and related litigation with Nerviano Medical Sciences S.r.l. over Cardiff’s core onvansertib license, completion of a $10 million registered direct offering to support working capital, and liquidity of approximately $34.5 million in cash, cash equivalents and short-term investments as of June 30, 2026, which together with reduced operating expenses is expected to fund operations into the third quarter of 2027 despite continued net losses.

Filing Facts

CIK

1213037

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-344645

Alert Tier

7